Adicet Bio, Inc. (ACET) — 10-Q Filings
All 10-Q filings from Adicet Bio, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Adicet Bio Narrows Q3 Loss, But Cash Reserves Dwindle
— Nov 5, 2025 Risk: high
Adicet Bio, Inc. reported a net loss of $26.856 million for the three months ended September 30, 2025, an improvement from the $30.478 million net loss in the s -
Adicet Bio Narrows Q2 Loss Amid R&D Spend Cuts
— Aug 7, 2025 Risk: high
Adicet Bio, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for the -
Adicet Bio Files Q1 2025 10-Q, Details Financials
— May 6, 2025 Risk: medium
Adicet Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly resTORbio, Inc., is focused on pharmaceutical preparations. Key fina -
Adicet Bio Files Q3 2024 10-Q, Discloses R&D Expenses
— Nov 6, 2024 Risk: medium
Adicet Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter of 2024 a -
Adicet Bio Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Adicet Bio, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial condition and business operations. The company, formerly known a -
Adicet Bio, Inc. Files 10-Q for Period Ending March 31, 2024
— May 14, 2024 Risk: medium
Adicet Bio, Inc. (ACET) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Adicet Bio, Inc. reported financial results for the quarter ended March 31
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX